Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

PVLA stock hub

Palvella Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

PVLAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.7B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

PVLA

In the news

Latest news · PVLA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-34.2

P25 -105.6P50 -46.5P75 -3.1

ROIC-17.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All PVLA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

156

Groups with data

Currency

USD

Showing 156 of 156 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001742961
Company name	Palvella Therapeutics, Inc.
Country	United States
Country code	US
Cusip	697947109
Employees	29
Enterprise value	$1.5B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US6979471090
Last refreshed	2026-05-10
Market cap	$1.7B
Market cap category	Small-Cap
Price	$121
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	PVLA
Website	https://palvellatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.84%
P/B ratio	7.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-49.3M
Net Income Growth Years	0%
Profit Per Employee	$-1.7M
ROA	-16.6
ROCE	-17.9
ROE	-34.25
ROIC	-17.73

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	450.21%
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$263.8M
Cash	$261.9M
Current Assets	$263.2M
Current Liabilities	$9.1M
Debt	$20.4M
Debt Equity	$0.09
Equity	$232.3M
Interest Coverage	-6.86
Liabilities	$31.4M
Long Term Assets	$528,000
Long Term Liabilities	$22.3M
Net Cash	$241.5M
Net Cash By Market Cap	$13.91
Net Cash Growth	286.54%
Net Debt Equity	$-1.04
Tangible Book Value	$232.3M
Tangible Book Value Per Share	$16.23

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	28.88
Net Working Capital	$-7.5M
Quick ratio	28.73
Working Capital	$254.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-159.41%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	449.57%
200-day SMA	88.14
50-day SMA	125.8
50-day SMA vs 200-day SMA	50over200
All Time High	151.2
All Time High Change	-19.77%
All Time High Date	2026-02-26
All Time Low	11.17
All Time Low Change	985.85%
All Time Low Date	2024-12-30
ATR	8.6
Beta1y	0.62
Beta2y	0.18
Ch YTD	15.88
High	121.7
High52	151.2
High52 Date	2026-02-26
High52ch	-19.77%
Low	113.6
Low52	20.2
Low52 Date	2025-06-18
Low52ch	500.45%
Ma50ch	-3.56%
Price vs 200-day SMA	37.61%
RSI	47.04
RSI Monthly	80.3
RSI Weekly	60.62
Sharpe ratio	2.42x
Sortino ratio	4.48
Total Return	-159.41%
Tr YTD	15.88
Tr1m	1.05%
Tr1w	-4.38%
Tr3m	47.56%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	14
Analyst Count Top	7
Analyst Price Target Top	$181
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.92
Operating Income	$-45.6M
Price target	$181
Price Target Change	$49.58
Price Target Change Top	$49.23

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	10,052,367%
Float Percent	70.23%
Shares Insiders	8.43%
Shares Institutions	62.5%
Shares Out	14,313,659
Shares Qo Q	10.2%
Shares Yo Y	159.41%
Short Float	19.69%
Short Ratio	7.29
Short Shares	13.83

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	214,041.45x
Bv Per Share	16.23
Ch1m	1.05
Ch1w	-4.38
Ch1y	449.6
Ch3m	47.56
Ch6m	55.84
Change	7.09%
Change From Open	6.76
Close	113.3
Days Gap	0.31
Dollar Volume	28,084,093.1
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-45.6M
EPS	$-4.19
F Score	2
Financing CF	215,273,000
Fiscal Year End	December
Founded	2,015
Investing CF	-55,440,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Ma150	100.7
Ma150ch	20.51%
Ma20	126.8
Ma20ch	-4.37%
Net CF	130,768,000
Next Earnings Date	2026-08-13
Open	113.6
Optionable	Yes
Position In Range	94.7
Post Close	121.3
Postmarket Change Percent	-2
Postmarket Price	$119
Ppne	528,000
Price Date	2026-05-08
Ptbv Ratio	7.47
Relative Volume	1.08x
Share Based Comp	8,683,000
Tr6m	55.84%
Us State	Pennsylvania
Volume	231,545

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does PVLA pay a dividend?

Capital-return profile for this ticker.

Performance

PVLA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns PVLA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+62.5%

Float: +70.2% of shares outstanding

Insider ownership

+8.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

PVLA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

47.0

Neutral momentum band

Price vs 200-day MA

+37.6%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

2.42

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About PVLA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current PVLA stock rating?

Palvella Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full PVLA analysis?

The full report lives at /stocks/PVLA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for PVLA?

The latest report frames PVLA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the PVLA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.